You've never seen anything like it · Doors open inStarts at 7:00 PM ET
Skip to content

Research compound · Other compounds research

Menotropins

Also known as HMG · menopausal gonadotropins

A preparation of gonadotropins purified from urine, containing follicle-stimulating and luteinizing hormone activities. A mixture of glycoproteins, not a peptide.

Compound type
Research compound
Research area
Other compounds

What it is

Menotropins is not a single molecule and not a peptide. It is a preparation purified from urine that carries two glycoprotein hormone activities, those of follicle-stimulating hormone and luteinizing hormone, together with urinary proteins carried through the purification.

Both hormones are heterodimers. Each consists of a common alpha subunit, shared across the glycoprotein hormone family, paired non-covalently with a hormone-specific beta subunit that determines which receptor the dimer engages 1. Each subunit is glycosylated, and the glycan structures vary between molecules of the same hormone.

Structure and chemistry

Because the preparation is a mixture of glycoproteins, it has no single molecular formula and no reference mass, and the source material records none. Each hormone is roughly 30 kDa, with the carbohydrate accounting for a substantial and variable share of that figure.

Two structural points matter for handling. The subunits are held together non-covalently, so conditions that denature protein, including extremes of pH, heat and some organic solvents, can dissociate the dimer and with it the activity that depends on the assembled form. Each subunit is also internally cross-linked by multiple disulfide bonds in a cystine-knot arrangement, so reducing agents are destructive. Crystallographic work on the assembled hormone and on its complex with the receptor ectodomain describes that architecture 1.

Analytical notes

A glycoprotein mixture is characterized rather than identified by a single expected ion. Intact mass spectrometry gives broad, heterogeneous envelopes because of glycan microheterogeneity, so the routine methods are size-exclusion chromatography for aggregation and dimer integrity, SDS-PAGE or capillary electrophoresis under reducing and non-reducing conditions to show subunit composition, isoelectric focusing to profile charge variants arising from sialic acid content, and released-glycan analysis.

Because the material is purified from a biological source rather than synthesized, lot-to-lot variation in glycan profile and in co-purified protein is expected, and the content of each hormone activity is established by bioassay or immunoassay rather than by weight.

Storage and handling in the laboratory

As supplied, the material is a lyophilized powder, stored cold, sealed and protected from light. Glycoprotein preparations are more sensitive than small peptides to freeze-thaw cycling and to surface adsorption at low concentration, so single-use aliquots and low-binding containers are standard practice for laboratories that will return to the material.

Open questions in the literature

For a mixture defined by activity rather than by structure, the open questions are compositional: which glycoforms are present in a given preparation, how the glycan profile varies between lots, and what fraction of the protein content is neither hormone. None of this is documented in the public literature for material carrying this name.

References

  1. Fan QR, Hendrickson WA. Assembly and structural characterization of an authentic complex between human follicle stimulating hormone and a hormone-binding ectodomain of its receptor. Molecular and Cellular Endocrinology. 2007;260-262:73-82. doi:10.1016/j.mce.2005.12.055. Source

For laboratory research use only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any disease.